Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel disease (IBD) condition — moderately to severely active Crohn’s disease ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

Widely used prescription medicines could get caught up in the Trump administration's tariff trade wars and EU retaliation.

Deb Gokie discusses the Arthritis Foundation's inclusive design program, emphasizing its impact on medical device and ...

Forget the old adage “it takes money to make money.” In the stock market, even a measly $500 can kickstart a fortune. Time, not a fat wallet, is the real MVP here. With the right picks, that modest ...

Incyte said on Monday its experimental drug has met the main goal in two separate late-stage studies testing it in patients with an inflammatory skin condition called hidradenitis suppurativa.

Incyte's experimental skin disease drug met the main goal of two separate late-stage trials, but data showed that it was not as effective as in its prior studies, sending the drugmaker's shares down ...

Stock market sell-offs are often great opportunities to buy dividend stocks. That's because dividend yields move in the ...

AbbVie (NYSE:ABBV) has recently seen promising developments with the release of favorable final results from the MIRASOL trial of ELAHERE, demonstrating significant improvements for women with ...